Nj State Employees Deferred Compensation Plan Verve Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $761 Million
- Q1 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 14,000 shares of VERV stock, worth $61,040. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$61,040
Previous $78,000
19.23%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.5MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$53.8 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$30.1 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$28.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$17.4 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$17.2 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $261M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...